Sam Brusco, Associate Editor04.05.23
JenaValve, maker of differentiated transcatheter aortic valve replacement (TAVR) systems, has appointed life sciences and medical device industry veteran Ken MacLeod, Ph.D. to its board of directors.
With over 35 years of experience in the industries, Dr. MacLeod is currently a partner at venture capital firm Rosetta Capital. He previously held senior operating roles at Abbott Labs and Serono SA. He also had life sciences fund management roles at SV Health Investors, Paul Capital, and Visium Healthcare Partners. Dr. MacLeod also serves on the board of Oxular Limited and had previous board roles at Pharming Group N.V. and On-X Life Technologies.
“We are very pleased to welcome Ken to the JenaValve Board of Directors,” John Kilcoyne, JenaValve CEO told the press. “His extensive background across life sciences, medical device operations, and investing will bring valuable perspective to our team.”
Dr. MacLeod stated, “I am honored to join JenaValve as the company continues on its mission to treat patients suffering from heart valve disease, including symptomatic, severe aortic regurgitation and stenosis. I look forward to bringing my experience to help the company navigate the challenges and, more importantly, the immense opportunities ahead.”
With over 35 years of experience in the industries, Dr. MacLeod is currently a partner at venture capital firm Rosetta Capital. He previously held senior operating roles at Abbott Labs and Serono SA. He also had life sciences fund management roles at SV Health Investors, Paul Capital, and Visium Healthcare Partners. Dr. MacLeod also serves on the board of Oxular Limited and had previous board roles at Pharming Group N.V. and On-X Life Technologies.
“We are very pleased to welcome Ken to the JenaValve Board of Directors,” John Kilcoyne, JenaValve CEO told the press. “His extensive background across life sciences, medical device operations, and investing will bring valuable perspective to our team.”
Dr. MacLeod stated, “I am honored to join JenaValve as the company continues on its mission to treat patients suffering from heart valve disease, including symptomatic, severe aortic regurgitation and stenosis. I look forward to bringing my experience to help the company navigate the challenges and, more importantly, the immense opportunities ahead.”